ClinicalTrials.gg
CompletedNCT02693197Updated Nov 24, 2017

PK Study of T-817 in Subjects With Hepatic Impairment

A Phase 1 interventional study of T-817MA in Healthy and Hepatic Impairment, sponsored by FUJIFILM Toyama Chemical Co., Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-24.

Sponsored by FUJIFILM Toyama Chemical Co., Ltd. · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was Aug 2016, 10 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective is to determine the single-dose pharmacokinetics (PK) of T-817 and T-817M5 (metabolite of T-817) in subjects with mild, moderate or severe hepatic impairment compared to matched healthy control subjects.

The secondary objective is to determine the safety and tolerability of single-dose T -817MA (Maleate salt of T-817) in subjects with mild, moderate or severe hepatic impairment.

02

Conditions studied

  • Healthy
  • Hepatic Impairment

Keywords

  • Hepatic Impairment
03

In context

Lead sponsor

FUJIFILM Toyama Chemical Co., Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For subjects with mild, moderate or severe hepatic impairment

  1. Adult male or female, 18 - 75 years of age
  2. Must weigh at least 50 kg and have a (BMI) ≥ 18.5 and ≤ 40.0 kg/m2
  3. Have mild, moderate or severe defined by classification hepatic impairment

For Matched Healthy Control Subjects Healthy adult male or female subjects will be matched 1:1 to a specific subject in the mild, moderate, or severe hepatic impairment cohort based upon age, weight, gender, and smoking status

Exclusion criteria

Exclusion Criteria:

  1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. History or presence of medical or psychiatric condition or disease in the opinion of the PI.
  3. History or presence of or idiosyncratic reaction to the study drug, related compounds, or inactive ingredients.
  4. Female subjects who are pregnant or lactating.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1:T-817MA

    Mild hepatic impairment subjects

    Drug: T-817MA

  • Experimental
    Cohort 2:T-817MA

    Healthy subjects matched to subjects in Cohort 1

    Drug: T-817MA

  • Experimental
    Cohort 3:T-817MA

    Moderate hepatic impairment subjects

    Drug: T-817MA

  • Experimental
    Cohort 4:T-817MA

    Healthy subjects matched to subjects in Cohort 3

    Drug: T-817MA

  • Experimental
    Cohort 5 :T-817MA

    Severe hepatic impairment subjects

    Drug: T-817MA

  • Experimental
    Cohort 6:T-817MA

    Healthy subjects matched to subjects in Cohort 5

    Drug: T-817MA

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma concentrations

    Time frame: 8 days

  2. Area under the plasma concentration time curve (AUC)

    Time frame: 8 days

  3. Maximum observed plasma concentration (Cmax)

    Time frame: 8 days

  4. Time to reach the maximum observed plasma concentration (tmax)

    Time frame: 8 days

  5. Apparent terminal elimination rate constant

    Time frame: 8 days

  6. Apparent terminal elimination half-life (t½)

    Time frame: 8 days

  7. Apparent total plasma clearance of unbound drug after oral (extravascular) administration (CL/F)

    Time frame: 8 days

  8. Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vd/F)

    Time frame: 8 days

  9. Metabolite to parent ratio (MPR)

    Time frame: 8 days

Secondary outcomes

  1. Number of participants with treatment-related adverse events

    Time frame: 8days

07

Study locations

2 sites
  • University of Miami
    Miami, Florida, United States
  • Orlando Clinical Research Center
    Orlando, Florida, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Aug 2016, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2016
First posted
Feb 26, 2016
StartActual
Feb 2016
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Last update
Nov 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02693197
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Collaborators
Celerion
Responsible party
Sponsor
First posted
Feb 26, 2016
Start date
Feb 2016
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Nov 24, 2017

Study contacts

Richard Preston, M.D.
principal investigator · University of Miami
Thomas Marbury, M.D.
principal investigator · Orlando Clinical Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: T-817 maleate

Start the discussion